Ipamorelin: 10MG

£29.99

Purity: ≥ 99%

£29.99

Ipamorelin: 10MG

Name: Ipamorelin: 10MG
Brand: Pure Grade Labs
Price: 29.99 GBP
Availability: OutOfStock

£29.99

Purity: ≥ 99%

£29.99

ENDOCRINE - GH & IGF-1 hormonal pathway stimulation research

BONE METABOLISM - Bone density, strength & skeletal health research

GASTROINTESTINAL - Gut motility & digestive recovery research

SELECTIVITY PROFILING - Targeted receptor action & cortisol independence research

Ipamorelin (INN; development code NNC 26-0161) is a synthetic pentapeptide and selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). It was originally developed by Novo Nordisk in the late 1990s as part of a systematic chemistry programme aimed at identifying highly selective growth hormone-releasing compounds. Ipamorelin was derived from GHRP-1 through the elimination of the central Ala-Trp dipeptide motif, which produced a compound with refined receptor selectivity.

Its primary mechanism of action is stimulation of growth hormone (GH) release from pituitary somatotrophs via the ghrelin receptor pathway. What distinguishes ipamorelin within the GHRP class is its specificity: unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate cortisol, ACTH, prolactin, FSH, LH, or TSH at doses many times the threshold required for GH stimulation. This selectivity profile has been the primary driver of its research interest.

Ipamorelin has been evaluated in Phase II clinical trials - specifically for the treatment of postoperative ileus (delayed return of gastrointestinal motility following surgery), which provides a basis of human pharmacokinetic and pharmacodynamic data not available for many research peptides.

Origin: Developed by Novo Nordisk in the 1990s. Derived from GHRP-1 through targeted modification to improve GH release selectivity. The result was the first GHS-R agonist with a selectivity profile comparable to endogenous GHRH.

Research Context: One of the more studied GHRPs with both preclinical animal data and human Phase II trial data (postoperative ileus, NCT00672074). Evidence base spans GH pharmacokinetics, bone metabolism, and gastrointestinal motility.

Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.85 g/mol

CAS Number: 170851-70-4

Form: Lyophilised Solid

The following summaries are drawn from peer-reviewed publications and registered clinical trial data indexed on PubMed and ClinicalTrials.gov. Pure Grade Labs does not interpret these findings as evidence of efficacy in humans beyond the specific conditions studied in clinical trials.

European Journal of Endocrinology: Ipamorelin: the first selective growth hormone secretagogue - pharmacological characterisation

Journal of Endocrinology: Ipamorelin counteracts glucocorticoid-induced inhibition of bone formation in adult rats

ClinicalTrials.gov / Phase II: Safety and efficacy of ipamorelin for management of post-operative ileus (NCT00672074)

References

https://pubmed.ncbi.nlm.nih.gov/9849822/

https://pubmed.ncbi.nlm.nih.gov/10373343/

https://pubmed.ncbi.nlm.nih.gov/10828840/

https://pubmed.ncbi.nlm.nih.gov/19289567/

https://pubmed.ncbi.nlm.nih.gov/25331030/

https://pubmed.ncbi.nlm.nih.gov/9733495/

https://pubmed.ncbi.nlm.nih.gov/9879640/

https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/

https://clinicaltrials.gov/study/NCT00672074

Every batch of Ipamorelin supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Ipamorelin is supplied as a lyophilised (freeze-dried) solid. As a small pentapeptide (711.85 g/mol), it is generally more stable than larger peptide sequences but remains sensitive to moisture, heat, and repeated freeze-thaw cycling. Follow the specifications below to preserve compound integrity.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to minimise moisture introduction.
Use bacteriostatic water (BAC water) as the reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl the vial until fully dissolved. Do not vortex or shake vigorously. Ipamorelin dissolves readily due to its small molecular weight.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter

Ipamorelin supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. Although ipamorelin has been evaluated in human Phase II clinical trials for a specific gastrointestinal indication, it has not received regulatory approval for human use from the FDA, MHRA, TGA, EMA, or any other authority.

This product is not a drug, medicine, or supplement and must not be used as such.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans beyond what is documented in registered clinical trial records.
This product must not be administered to humans or animals outside of a licensed research context.
Ipamorelin is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category. Athletes subject to drug testing should be aware of this classification.
The legal and regulatory status of ipamorelin varies by jurisdiction. Purchasers are solely responsible for verifying compliance with all applicable laws and regulations in their country before ordering.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.